Evidence mapPaperPMID 36575356Full record

ReviewPulmonary therapy2023

Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity.

Derek Ge, Dinah Foer, Katherine N Cahill

Open access · goldAbstract readReview
In one paragraph

Review in Pulmonary therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Management of the pediatric patient with asthma and obesity.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2024
    Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Derek GeRutgers Robert Wood Johnson Medical School, Piscataway, NJ, USA.
Dinah FoerDivision of General Internal Medicine and Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA, USA.
Katherine N CahillDivision of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 450, Nashville, TN, 32703, USA. Katherine.cahill@vumc.org.ORCID http://orcid.org/0000-0002-8549-1835
Brigham and Women's Hospital · USRutgers, The State University of New Jersey · USVanderbilt University Medical Center · US

Funding

Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic AsthmaU01AI155299 · VANDERBILT UNIVERSITY MEDICAL CENTER · 2025 to 2025
$2.3M
Effects of GLP-1 Receptor Agonists on Airway Inflammation and Platelet Activation in AsthmaK23HL161332 · BRIGHAM AND WOMEN'S HOSPITAL · 2025 to 2025
$195k
NHLBI NIH HHS K23 HL161332NIAID NIH HHS U01 AI155299
6 · The paper itself

Abstract

Adults with obesity may develop asthma that is ineffectively controlled by inhaled corticosteroids and long-acting beta-adrenoceptor agonists. Mechanistic and translational studies suggest that metabolic dysregulation that occurs with obesity, particularly hyperglycemia and insulin resistance, contributes to altered immune cell function and low-grade systemic inflammation. Importantly, in these cases, the same proinflammatory cytokines believed to contribute to insulin resistance may also be responsible for airway remodeling and hyperresponsiveness. In the past decade, new research has emerged assessing whether hypoglycemic therapies impact comorbid asthma as reflected by the incidence of asthma, asthma-related emergency department visits, asthma-related hospitalizations, and asthma-related exacerbations. The purpose of this review article is to discuss the mechanism of action, preclinical data, and existing clinical studies regarding the efficacy and safety of hypoglycemic therapies for adults with obesity and comorbid asthma.

Indexed as

Body mass indexDPP-4 inhibitorsGLP-1R agonistsIncretinsInsulinMetforminSGLT-2 inhibitorsSulfonylureasThiazolidinedionesType 2 diabetes

Identifiers

PMID36575356
PMCPMC9931991
OpenAlexW4313237593

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.